N-Terminal Myristoylation Detection: Comprehensive Protein Lipidation Analysis Services

N-terminal myristoylation is a critical protein lipid modification in which a 14-carbon myristoyl group is covalently attached to the N-terminal glycine residue, regulating membrane association, protein-protein interactions, and intracellular signaling. Our professional N-terminal myristoylation detection service combines metabolic labeling, click chemistry enrichment, and high-resolution LC-MS/MS to deliver accurate, site-specific identification of myristoylated proteins and modification sites. With optimized workflows for diverse sample types, we support researchers in signal transduction, oncology, virology, and drug discovery projects worldwide.

Technical Overview

N-terminal myristoylation (N-myristoylation) is a ubiquitous and essential protein post-translational modification in eukaryotes, catalyzed by N-myristoyltransferase (NMT). During this process, a myristoyl group—derived from myristic acid (tetradecanoic acid, C14:0)—is covalently attached via an amide bond to the α-amino group of an N-terminal glycine residue. This modification typically occurs co-translationally after the initiator methionine is removed by methionine aminopeptidase (MetAP), although post-translational N-myristoylation can also occur on internal glycine residues exposed following proteolytic cleavage, such as during apoptosis.

N-myristoylation plays a fundamental role in regulating protein localization and function. The attached myristoyl moiety functions as a hydrophobic membrane anchor, facilitating the association of modified proteins with cellular membranes. In addition, myristoylation works in concert with other signals—such as polybasic domains, palmitoylation, or protein-protein interactions—to achieve reversible membrane binding through "myristoyl switch" mechanisms. Well-characterized myristoylated proteins include Src-family kinases, G-protein α subunits, ADP-ribosylation factors (Arfs), MARCKS, recoverin, and numerous viral proteins such as HIV-1 Nef and Gag polyprotein.

Because dysregulated N-myristoylation is closely linked to cancer progression, parasitic infections, and viral pathogenesis, accurate detection and quantification of this modification has become increasingly important in both basic research and drug development. N-myristoyltransferase has emerged as a validated therapeutic target in oncology and tropical disease research, making reliable analytical detection of myristoylation events a critical capability for modern proteomics laboratories.

Testing Samples

Cell Samples

Cultured mammalian cells (adherent or suspension), insect cells, yeast, and bacterial expression systems are the most common sample types for myristoylation analysis. Cells can be metabolically labeled in culture with modified myristic acid analogs prior to harvest, enabling robust enrichment of newly myristoylated proteins. A typical submission requires 1–5 × 10⁷ cells per condition, harvested and washed to remove culture medium contaminants. Both treated and control groups are recommended to enable comparative analysis.

Tissue Samples

Animal tissues, tumor biopsies, and plant tissues can be analyzed for endogenous myristoylation. Fresh-frozen tissue is preferred to preserve labile lipid modifications. Recommended input is 50–200 mg of tissue per sample. For ex vivo metabolic labeling, tissue slices may be incubated with alkyne-tagged myristic acid analogs to capture active myristoylation events.

Protein Samples

Purified recombinant proteins, immunoprecipitated protein complexes, and total cell lysates are accepted for targeted myristoylation verification. Purified proteins should be supplied at a concentration of at least 0.1–0.5 mg/mL in a mild buffer compatible with downstream mass spectrometry. For immunoprecipitated samples, co-immunoprecipitation of the target protein followed by LC-MS/MS confirmation is a standard workflow for validating myristoylation on specific proteins of interest.

Parasite and Microorganism Samples

Given that NMT is a validated drug target in protozoan parasites such as Plasmodium falciparum, Leishmania species, and Trypanosoma brucei, we accept parasite lysates and engineered expression systems for comparative myristoylome profiling between treated and untreated populations.

Testing Items

Our N-terminal myristoylation detection service encompasses a comprehensive portfolio of analytical items tailored to different research objectives:

• Global myristoylome profiling: large-scale identification of myristoylated proteins across the entire proteome using metabolic labeling and click chemistry enrichment coupled with LC-MS/MS.
• Site-specific myristoylation mapping: precise localization of myristoylated glycine residues at N-termini and internal cleavage-generated sites.
• Targeted myristoylation validation: confirmation of myristoylation status on specific proteins of interest via immunoprecipitation followed by mass spectrometric detection.
• Comparative quantification: relative quantification of myristoylation changes between experimental conditions using label-free or TMT-based approaches.
• NMT activity assessment: evaluation of N-myristoyltransferase activity and inhibitor efficacy through substrate myristoylation readouts.
• Bioinformatics prediction: computational prediction of candidate myristoylated substrates using sequence motif analysis and machine-learning-based algorithms.
• Functional annotation: Gene Ontology, KEGG pathway, and protein interaction network analysis of identified myristoylated proteins.

Testing Methods

Bioinformatic Prediction

Initial screening for candidate myristoylated proteins is performed using prediction tools that evaluate the N-terminal sequence context. Key criteria include an N-terminal glycine residue at position 2, a favorable downstream sequence (positions 3–6 favoring Ser, Thr, Lys, Arg, Asn, Gln, or acidic residues), and the absence of proline at position 3. Tools such as Myristoylator, NMT Predictor, and TermiNator provide complementary predictions that guide subsequent experimental validation.

Metabolic Labeling with Functionalized Myristic Acid Analogs

Living cells are cultured in the presence of bioorthogonal myristic acid analogs, such as alkynyl-myristic acid (YnMyr, 13-tetradecynoic acid) or azido-myristic acid (AzMyr). These analogs are efficiently recognized by cellular acyl-CoA synthetases and N-myristoyltransferase, incorporating the chemical handle into newly synthesized myristoylated proteins while minimally perturbing native biology.

Click Chemistry Enrichment

Following lysis, the bioorthogonal tag on myristoylated proteins is reacted via copper-catalyzed azide-alkyne cycloaddition (CuAAC) with complementary azide- or alkyne-functionalized biotin reagents. The biotinylated myristoylated proteins are then selectively enriched on streptavidin agarose resin, dramatically enhancing detection sensitivity by removing the high background of unmodified proteins.

LC-MS/MS Identification and Site Mapping

Enriched proteins are on-bead digested with sequencing-grade proteases (trypsin, chymotrypsin, or complementary enzymes). Resulting peptides are analyzed by high-resolution nanoLC-MS/MS on Orbitrap-class instruments. Myristoylated N-terminal peptides are identified by characteristic mass shifts (+210.198 Da for the myristoyl group on glycine) and confirmed by diagnostic fragment ions in MS/MS spectra. Strict false discovery rate control (FDR ≤ 1%) is applied at peptide, protein, and modification-site levels.

Classic Radiolabeling Verification

For validation of individual substrates, classical metabolic labeling with radiolabeled [³H]-myristic acid followed by SDS-PAGE autoradiography or fluorography remains a gold-standard confirmatory approach, particularly useful for demonstrating inhibitor-sensitive incorporation.

Distinguishing Myristoylation from Palmitoylation

Because myristoylation and S-palmitoylation often co-occur on the same proteins, our workflows incorporate analytical controls to distinguish the two modifications, including acyl-biotin exchange (ABE) comparison, acyl-resistance assays, hydroxylamine treatment controls, and high-confidence MS/MS-based site assignment to N-terminal glycine versus cysteine residues.

Applications

N-terminal myristoylation detection services support a wide range of research and translational applications:

• Signal transduction research: dissecting the membrane recruitment mechanisms of Src-family kinases, heterotrimeric G-proteins, and calcium sensor proteins.
• Cancer biology: identifying oncogenic myristoylation events, such as c-Src hyperactivation in colon cancer, and characterizing NMT overexpression in tumor progression.
• Apoptosis studies: detecting post-translational myristoylation of caspase cleavage products such as tBid, actin, and gelsolin fragments during programmed cell death.
• Antiviral and antimicrobial drug development: profiling myristoylation-dependent viral proteins (e.g., HIV-1 Nef, Gag; rotavirus VP2) and evaluating NMT inhibitors as broad-spectrum antivirals.
• Anti-parasitic therapeutic discovery: quantitative myristoylomics in Plasmodium, Leishmania, and Trypanosoma to assess NMT inhibitor target engagement and resistance mechanisms.
• Membrane trafficking and vesicle transport: functional analysis of Arf family GTPases and their regulators in Golgi dynamics.
• Biopharmaceutical characterization: verifying correct N-myristoylation of engineered or recombinant protein therapeutics and biosimilars.
• Biomarker discovery: mining disease-associated myristoylation signatures for diagnostic and prognostic applications.

FAQ

What sample quantity is required for myristoylation detection?

For global myristoylome profiling, we recommend 1–5 × 10⁷ cells or 50–200 mg of tissue per sample. For targeted validation of individual proteins, immunoprecipitation-grade lysate containing at least 10–100 µg of the target protein region is typically sufficient. Lower inputs may be feasible after feasibility assessment by our technical team.

Can endogenous myristoylation be detected without metabolic labeling?

Yes. Direct LC-MS/MS analysis of enriched or purified proteins can detect endogenous myristoylated N-terminal peptides, although sensitivity is lower than metabolic labeling approaches. For low-abundance targets, immunoprecipitation enrichment combined with optimized digestion strategies is recommended.

How do you distinguish N-terminal myristoylation from palmitoylation?

Our analysis relies on MS/MS-based site localization: myristoylation is attached to the N-terminal glycine via a stable amide bond, whereas palmitoylation occurs on cysteine residues via a labile thioester bond. Complementary hydroxylamine sensitivity assays and distinct mass shifts provide unambiguous differentiation between the two lipid modifications.

Is it possible to quantify changes in myristoylation between treatment groups?

Yes. We offer label-free quantification and TMT multiplexing strategies that enable relative quantification of myristoylation changes across up to 16 experimental conditions in a single LC-MS/MS run, with statistical analysis of biological replicates provided in the final report.

What is the typical turnaround time?

Standard projects are completed within 3–5 weeks, depending on sample type, number of conditions, and data analysis complexity. Bioinformatics prediction-only services can typically be delivered within 5–7 business days.

How is data quality controlled?

All LC-MS/MS analyses employ instrument QC standards, peptide and protein FDR thresholds of ≤ 1%, manual verification of modification-site spectra, and biological replicate consistency checks. Comprehensive raw data, processed results, and a detailed technical report are provided with every project.